Codexis, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Codexis, Inc. now
Current reporting with the operating signal separated from the noise.
Codexis, Inc. Appoints Dr. Arthur Levin to Strategic Advisory Board to Enhance Oligonucleotide Expertise
The story matters when it changes Codexis, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Codexis, Inc. Appoints Christos Richards to Board of Directors
The story matters when it changes Codexis, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Codexis, Inc.
The story matters when it changes Codexis, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Codexis, Inc. (CDXS) CEO John Nicols on Q2 2022 Results
The story matters when it changes Codexis, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Codexis, Inc. (CDXS) CEO John Nicols on Q4 2021 Results
The story matters when it changes Codexis, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Latest CDXS filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Codexis, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →